Sobre

 

Coordenação
Fabio Mansani e Felipe Zerwes

08:00 – 08:45

ABERTURA

Oral and Posters Local, Regional and Adjuvant

CDIS - Estadiamento (15’)
Antonio Frasson
Abstract 508
Primary results of NRG Oncology / NSABP B-43: Phase III trial comparing concurrent trastuzumab (T) and radiation therapy (RT) with RT alone for women with HER2-positive ductal carcinoma in situ (DCIS) after lumpectomy.

Abstract 519
Ipsilateral invasive cancer risk after diagnosis with ductal carcinoma in situ (DCIS): Comparison of patients with and without index surgery.

Abstract 563
Clinical utility of 18F-FDG-PET/CT in staging localized breast cancer prior to initiating preoperative systemic therapy.

Prognóstico pré-tratamento (15’)
Lucas Budel
Abstract 583
Prognostic impact of high stromal tumor-infiltrating lymphocytes (sTIL) in the absence of pathologic complete response (pCR) to neoadjuvant therapy (NAT) in early stage triple negative breast cancer (TNBC).

Abstract 535
Real-world patterns of treatment and recurrence by frailty status among older women with HR-positive, HER2-negative early breast cancer.

Abstract 542
Association of intraoperative opioids with improved recurrence-free survival in triple negative breast cancer.

Abstract Brazil (5’)
Andrea Pereira
- Overview of obesity and breast cancer in Brazil: 24 year of follow up.

Discussão (10’)
Darley Ferreira, Rafael Machado

08:45 – 09:40

Cirurgia – Axila
Marina Ávila (15’)
Abstract 564
Can sentinel node biopsy after neoadjuvant systemic chemotherapy (NAC) be safely omitted in selected patient with early breast cancer?

Abstract 567
Factors associated with axillary conversion after neoadjuvant chemotherapy in initially node positive breast cancer patients: A transSENTINA analysis.

Abstract 572
Impact of axillary lymph node dissection (ALND) on survival in patients with ypN1 breast cancer that receive regional nodal irradiation (RNI): A national cancer database (NCDB) analysis.

Neoadjuvância - 1 (15’)
Leonardo Ribeiro Soares
Abstract 505
Letrozole + ribociclib versus letrozole + placebo as neoadjuvant therapy for ER+ breast cancer (FELINE trial).

Abstract 515
De-escalated chemotherapy versus endocrine therapy plus pertuzumab+ trastuzumab for HR+/HER2+ early breast cancer (BC): First efficacy results from the neoadjuvant WSG-TPII study.

Abstract 587
Efficacy of neoadjuvant chemotherapy (NAC) in male breast cancer (MaBC) compared with female breast cancer (FBC): A National Cancer Database (NCDB) study.

Neoadjuvância - 2 (15’)
Renata Brondi
Abstract 565
Artificial intelligence to accurately identify breast cancer patients with a pathologic complete response for omission of surgery after neoadjuvant systemic therapy: An international multicenter analysis.

Abstract 594
Prediction of response to neoadjuvant hormonal therapy (NAHT) using upfront oncotype Dx recurrence score (RS): Results from the SAFIA phase III trial.

Abstract 514
Response to neoadjuvant chemotherapy and the 21-gene breast recurrence score in Young women with estrogen receptor-positive early breast cancer.

Discussão (10’)
Daniel Argolo, Waldeir de Almeida Junior

09:40 – 10:25

Abstract Brazil (10’)
André Mattar
- Practice-changing use of 21-gene oncotype DX breast recurrence score assay in a public hospital in Brazil: Results of 155 cases.
- Economic evaluation of the oncotype DX test for hormone receptor positive (HR+) early-stage breast cancer (BC) from the Brazilian societal perspective.

Adjuvância (20’)
Daniel Buttros
Abstract 512
Breast cancer index (BCI) predicts benefit of two-and-a-half versus five years of extended endocrine therapy in HR+ breast cancer patients treated in the ideal trial.

Abstract 523
Does chemotherapy affect survival of breast cancer (BC) patients with recurrence score 26-30?

Abstract 524
Statistical machine learning model to predict Oncotype DX risk category in women over age 50.

Abstract 537
Impact of delays in initiation of adjuvant endocrine therapy and survival among patients with breast cancer.

Abstract Brazil (5’)
Luiz Henrique Gebrim
- Prognostic factors impacting survival in early HER2-positive breast cancer (BC): Results from a 1,142 patients database study.

Discussão (10’)
Adriana Freitas, Vilmar Marques

INTERVALO (15’)

10:40 – 11:40

Cancer Prevention, Risk Reduction and Genetics
(20’)
Alessandra Borba e Fabiana Makdissi

Breast Cancer Highlights Local, Regional and Adjuvant (25’)
Ruffo de Freitas Junior

Discussão (15’)
Cesar Cabello, Francisco Pimentel

11:40 – 12:35

Breast Cancer Metastatic (30’)
Marina Sahade e Max Mano

Plenary Session (10’)
Giuliano Tosello
- A randomized phase III trial of systemic therapy plus early local therapy versus systemic therapy alone in women with de novo stage IV breast cancer: A trial of the ECOG-ACRIN Research Group (E2108).

Discussão 15’
João Nunes, José Francisco Rinaldi

ENCERRAMENTO

 

Professores

Conheça nosso time.

Fale Conosco